ワシントンにおけるバーキットリンパ腫の臨床試験
ワシントン内の拠点で、バーキットリンパ腫に関する11件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- 他1件
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中
18歳以上 · 全性別 · 2026/08/19更新 · NCT06710418Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相健康なボランティア歓迎
6 Months · 全性別 · 2026/05/29更新 · NCT04195633Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/23更新 · NCT07097363Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Fred Hutchinson Cancer Research Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/05更新 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。